1. Date of download: 6/22/2016 Copyright © 2016 American Medical Association. All rights reserved. From: An In Vivo Evaluation of Docetaxel Delivered Intratumorally in Head and Neck Squamous Cell Carcinoma Arch Otolaryngol Head Neck Surg. 2005;131(5):418-429. doi:10.1001/archotol.131.5.418 Changes in tumor weight in mice following intratumoral delivery of docetaxel or control (diluent) in (A) HN30 and (B) HN12 xenograft head and neck squamous cell carcinoma models. Figure Legend:

2. Date of download: 6/22/2016 Copyright © 2016 American Medical Association. All rights reserved. From: An In Vivo Evaluation of Docetaxel Delivered Intratumorally in Head and Neck Squamous Cell Carcinoma Arch Otolaryngol Head Neck Surg. 2005;131(5):418-429. doi:10.1001/archotol.131.5.418 Changes in body weight of SCID mice (severe combined immunodeficiency disorder) treated with intratumoral docetaxel or control (diluent) in (A) HN30 and (B) HN12 xenograft head and neck squamous cell carcinoma models. Figure Legend:

3. Date of download: 6/22/2016 Copyright © 2016 American Medical Association. All rights reserved. From: An In Vivo Evaluation of Docetaxel Delivered Intratumorally in Head and Neck Squamous Cell Carcinoma Arch Otolaryngol Head Neck Surg. 2005;131(5):418-429. doi:10.1001/archotol.131.5.418 Toxic effects on BALB/c mice of subcutaneously injected docetaxel: (A) weight loss; (B) alopecia; and (C) skin erosion. Figure Legend:

4. Date of download: 6/22/2016 Copyright © 2016 American Medical Association. All rights reserved. From: An In Vivo Evaluation of Docetaxel Delivered Intratumorally in Head and Neck Squamous Cell Carcinoma Arch Otolaryngol Head Neck Surg. 2005;131(5):418-429. doi:10.1001/archotol.131.5.418 Changes in docetaxel levels in mice following intratumoral (IT) and intravenous (IV) administration of a single injection (15 mg/kg) in the pilot (A) and definitive (B and C) pharmacokinetic studies of HN12 xenografts. Figure Legend:

5. Date of download: 6/22/2016 Copyright © 2016 American Medical Association. All rights reserved. From: An In Vivo Evaluation of Docetaxel Delivered Intratumorally in Head and Neck Squamous Cell Carcinoma Arch Otolaryngol Head Neck Surg. 2005;131(5):418-429. doi:10.1001/archotol.131.5.418 Microscopic views of HN12 and HN30 cells after 24 hours of exposure to docetaxel at 0, 100, and 1000 ng/mL. Figure Legend:

6. Date of download: 6/22/2016 Copyright © 2016 American Medical Association. All rights reserved. From: An In Vivo Evaluation of Docetaxel Delivered Intratumorally in Head and Neck Squamous Cell Carcinoma Arch Otolaryngol Head Neck Surg. 2005;131(5):418-429. doi:10.1001/archotol.131.5.418 Protein expression patterns of cell cycle regulators in head and neck squamous cell carcinoma cells after exposure to different concentrations of docetaxel for 6 and 24 hours. Figure Legend:

7. Date of download: 6/22/2016 Copyright © 2016 American Medical Association. All rights reserved. From: An In Vivo Evaluation of Docetaxel Delivered Intratumorally in Head and Neck Squamous Cell Carcinoma Arch Otolaryngol Head Neck Surg. 2005;131(5):418-429. doi:10.1001/archotol.131.5.418 Protein expression patterns of regulators of apoptosis in head and neck squamous cell carcinoma cells after exposure to different concentrations of docetaxel for 6 and 24 hours. Figure Legend:

8. Date of download: 6/22/2016 Copyright © 2016 American Medical Association. All rights reserved. From: An In Vivo Evaluation of Docetaxel Delivered Intratumorally in Head and Neck Squamous Cell Carcinoma Arch Otolaryngol Head Neck Surg. 2005;131(5):418-429. doi:10.1001/archotol.131.5.418 Protein expression patterns of signal transduction molecules in head and neck squamous cell carcinoma cells after exposure to different concentrations of docetaxel for 6 and 24 hours. Figure Legend: